FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Harish Dave, MD
Medical Monitor
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uz Leuven
Leuven, Belgium
- Universitätsklinikum Erlangen
Erlangen, Germany
- Universitätsklinikum Essen (aör) Klinik Für Frauenheilkunde Und Geburtshilfe
Essen, Germany
- Universitäts-Frauenklinik Dept. Für Frauengesundheit
Tübingen, Germany
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
- Mitchell Cancer Institute - Usa Health System
Mobile, Alabama, United States
- Arizona Oncology Associates, Pc - Hal
Phoenix, Arizona, United States
- Arizona Oncology Associates, Pc - Hope
Tucson, Arizona, United States
- University of Arizona Cancer Center
Tucson, Arizona, United States
- Oncology Institute of Hope and Innovation
Lynwood, California, United States
- University of California Irvine
Orange, California, United States
- California Pacific Medical Center, Research Institute
San Francisco, California, United States
- Sansum Clinic
Santa Barbara, California, United States
- Rocky Mountain Cancer Centers, Llp
Lakewood, Colorado, United States
- Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering
Hartford, Connecticut, United States
- Stamford Hospital - Bennett Cancer Center
Stamford, Connecticut, United States
- Baptist Health Medical Group Oncology, Llc
Miami, Florida, United States
- Sylvester Comprehensive Cancer Center University of Miami
Miami, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Augusta University
Augusta, Georgia, United States
- Maine Medical Center
Scarborough, Maine, United States
- Mercy Medical Center; the Institute for Cancer Care
Baltimore, Maryland, United States
- Hca Midwest Division - Sarah Cannon Cancer Institute
Kansas City, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Gabrail Cancer Center
Canton, Ohio, United States
- Oklahoma Heath Sciences Center - Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Tulsa Cancer Institute
Tulsa, Oklahoma, United States
- Ohsu Center for Women'S Health & Knight Cancer Institute
Portland, Oregon, United States
- Willamette Valley Cancer Institute
Springfield, Oregon, United States
- Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering
Allentown, Pennsylvania, United States
- the Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States
- Gibbs Cancer Center & Research Institute Spartanburg Medical Center
Spartanburg, South Carolina, United States
- Texas Oncology, P.A.
Austin, Texas, United States
- Texas Oncology
Bedford, Texas, United States
- Dallas County Hospital District D/b/a Parkland Health and Hospital System
Dallas, Texas, United States
- Simmons Comprehensive Cancer Center; Ut Southwestern Medical Center
Dallas, Texas, United States
- Texas Oncology, P.A.
Dallas, Texas, United States
- Texas Oncology San Antonio
San Antonio, Texas, United States
- Texas Oncology, P.A.
The Woodlands, Texas, United States
- Texas Oncology, P.A.
Tyler, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2016
- Primary completion
- 31 Oct 2017
- Completion
- 31 Oct 2017
- Last update posted
- 24 Mar 2025
- Registered enrollment
- 70
- Registry id
- NCT02641639
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.